Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Correvio Pharma Corp. CORV

Healthcare Drug Manufacturers - Major
Correvio Pharma Corp is specialty pharmaceutical company. It offers patients and healthcare providers therapeutic solutions for acute medical conditions to improve health and quality of life. Its products are Aggrastat, Esmocard, Brinavess, Xydalba, Zevtera/Mabelio, and others. It offers solutions on Acute Bacterial Skin and Skin Structure Infections, Acute Coronary Syndromes, Atrial Fibrillation, Hospital Acquired Pneumonia & Community Acquired Pneumonia, Pulmonary Arterial Hypertension, and Su


NDAQ:CORV - Post by User

Correvio Pharma Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(9)
•••
Post by XXX28XXXon Dec 06, 2019 2:32pm
113 Views
Post# 30429980

FDA meeting set for Dec 10 2019 to review

FDA meeting set for Dec 10 2019 to reviewdrug Brinvess.....the sell off in price today kinda makes you wonder how that meeting will go....alot of price pressure....somebody knows something....the question is what and its not likely good news....
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities